Life-sciences go through a number of data challenges that force the scientific community to rethink many aspects of data management. To encounter these challenges and to share data amongst European researchers, the ELIXIR initiative was launched. ELIXIR is an intergovernmental organisation that brings together life-science resources from across Europe. It coordinates, integrates and sustains bioinformatics resources across its member states and enables users in academia and industry to access vital services for their research. Belgium recently joined ELIXIR as a full member. The Belgian ELIXIR node is coordinated by the VIB-UGent Center for Plant Systems Biology.
This year, Galapagos will hire seventy new employees. Galapagos is growing so fast, that the company staff no longer fits into one building. "Since last year, we are located in two buildings in the industrial zone Mechelen Noord. We are currently looking for a larger building in Mechelen," says Evelyn Fox, spokeswoman for Galapagos. "There are 180 people working in Mechelen, and this number will be increased with seventy extra empolyess. We are especially looking for doctors, project managers and people who are skilled in legislation. These people should have the necessary experience."
In the Phase II TITAN study, treatment with caplacizumab significantly reduced the time to platelet count normalisation and the number of recurrences of aTTP while on drug treatment. Post-hoc analysis of the TITAN study demonstrated that caplacizumab dramatically reduced the number of patients experiencing major thromboembolic events while on drug treatment. Ablynx is on track to report results of the confirmatory Phase III HERCULES study in the second half of 2017 and these results are expected to support a BLA filing in the United States in 2018. Ablynx intends to lead the commercialisation of caplacizumab in Europe and North America.
Life-sciences go through a number of data challenges that force the scientific community to rethink many aspects of data management. To encounter these challenges and to share data amongst European researchers, the ELIXIR initiative was launched. ELIXIR is an intergovernmental organisation that brings together life-science resources from across Europe. It coordinates, integrates and sustains bioinformatics resources across its member states and enables users in academia and industry to access vital services for their research. Belgium recently joined ELIXIR as a full member. The Belgian ELIXIR node is coordinated by the VIB-UGent Center for Plant Systems Biology.
This year, Galapagos will hire seventy new employees. Galapagos is growing so fast, that the company staff no longer fits into one building. "Since last year, we are located in two buildings in the industrial zone Mechelen Noord. We are currently looking for a larger building in Mechelen," says Evelyn Fox, spokeswoman for Galapagos. "There are 180 people working in Mechelen, and this number will be increased with seventy extra empolyess. We are especially looking for doctors, project managers and people who are skilled in legislation. These people should have the necessary experience."
In the Phase II TITAN study, treatment with caplacizumab significantly reduced the time to platelet count normalisation and the number of recurrences of aTTP while on drug treatment. Post-hoc analysis of the TITAN study demonstrated that caplacizumab dramatically reduced the number of patients experiencing major thromboembolic events while on drug treatment. Ablynx is on track to report results of the confirmatory Phase III HERCULES study in the second half of 2017 and these results are expected to support a BLA filing in the United States in 2018. Ablynx intends to lead the commercialisation of caplacizumab in Europe and North America.